SOLV Solventum (SOLV) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001964738
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
379
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $0 priced
What the filings say about SOLV
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2025-12-31
Solventum insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Solventum Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 29.3% of the 5,039 shares held after it.
- No other insider bought within 30 days.
- 379 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendell Amy McBride bought about $100.3K of SOLV on Mar 10, 2026, the largest insider purchase at the company on our record; 379 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 34.4% of the 25,569,190 shares held after it.
- No other insider sold within 30 days.
- 379 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider 3M CO sold about $646.4M of SOLV on Aug 15, 2025, the largest insider sale at the company on our record; 379 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
379 funds bought in last quarter
more than 91% of Medical Devices
Revenue
+0.9% year over year
below 76% of Medical Devices
Margin
18.7% net margin
more than 92% of Medical Devices
Buybacks
$355.0M repurchased, FY to 2026-06-30
more than 80% of Medical Devices
Short interest
3.4% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
below 57% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SOLV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+18.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SOLV: institutional holders (13F)
13F holdings, latest reported quarter
16,170,038 sh
$1.2B
9,761,863 sh
$753.1M
9,624,829 sh
$742.6M
8,236,753 sh
$635.5M
6,328,641 sh
$488.3M
Congress trades in SOLV
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-12-31 · disclosed 23 days later
$15,001 - $50,000
Sold 2025-01-15 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SOLV planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SOLV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P Spin-Off ETF
$12.0M position · as of 2026-07-31
5.3%
Independent Franchise Partners US Equity Fund
$67.1M position · as of 2026-06-30
5.0%
LONE PEAK VALUE FUND
$7.9M position · as of 2026-06-30
4.6%
StockSnips AI-Powered Sentiment US All Cap ETF
$727.9K position · as of 2026-07-31
3.7%
Davis Opportunity Fund
$23.5M position · as of 2026-06-30
3.6%
Nuance Concentrated Value Fund
$1.3M position · as of 2026-07-31
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Bryan C. Hanson
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$20.1M
$40.0M
$5.1M
+15%
+9%
2024
$40.0M
$40.2M
$8.5M
-4%
-5%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 379 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SOLV financials
Revenue growth
+0.9%
XBRL, annual
Net margin
18.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SOLV
| FY Dec 2025 | $8.3B |
| FY Dec 2024 | $8.3B |
| FY Dec 2023 | $8.2B |
| FY Dec 2022 | n/a |
| Jun 2026 | $2.2B |
| Mar 2026 | $2.0B |
| Dec 2025 | $2.0B |
| Sep 2025 | $2.1B |
| Jun 2025 | $2.2B |
| Mar 2025 | $2.1B |
| Dec 2024 | $2.1B |
| Sep 2024 | $2.1B |
At each fiscal year end
Single quarter
Net margin, TTM
+17.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SOLV
| FY Dec 2025 | +18.7% |
| FY Dec 2024 | +5.8% |
| FY Dec 2023 | +16.4% |
| FY Dec 2022 | n/a |
| Jun 2026 | +4.2% |
| Mar 2026 | +0.6% |
| Dec 2025 | +3.2% |
| Sep 2025 | +60.4% |
| Jun 2025 | +4.2% |
| Mar 2025 | +6.6% |
| Dec 2024 | +1.5% |
| Sep 2024 | +5.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$118.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SOLV
| FY Dec 2025 | -$10.0M |
| FY Dec 2024 | $805.0M |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | n/a |
| Jun 2026 | $144.0M |
| Mar 2026 | -$273.0M |
| Dec 2025 | $32.0M |
| Sep 2025 | -$21.0M |
| Jun 2025 | $59.0M |
| Mar 2025 | -$80.0M |
| Dec 2024 | $92.0M |
| Sep 2024 | $76.0M |
At each fiscal year end
Single quarter
Debt to equity
1.06x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity SOLV
| FY Dec 2025 | 1.00x |
| FY Dec 2024 | 2.71x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| Jun 2026 | 1.06x |
| Mar 2026 | 1.02x |
| Dec 2025 | 1.00x |
| Sep 2025 | 1.03x |
| Jun 2025 | 2.14x |
| Mar 2025 | 2.43x |
| Dec 2024 | 2.71x |
| Sep 2024 | 2.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.04x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt SOLV
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.15x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.04x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.15x |
| Sep 2024 | 0.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+34.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SOLV
| FY Dec 2025 | +38.9% |
| FY Dec 2024 | +6.6% |
| FY Dec 2023 | +11.5% |
| FY Dec 2022 | n/a |
| Jun 2026 | +34.0% |
| Mar 2026 | +34.8% |
| Dec 2025 | +38.9% |
| Sep 2025 | +37.3% |
| Jun 2025 | +11.7% |
| Mar 2025 | +10.7% |
| Dec 2024 | +6.6% |
| Sep 2024 | +9.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SOLV
| FY Dec 2025 | +10.8% |
| FY Dec 2024 | +3.4% |
| FY Dec 2023 | +9.7% |
| FY Dec 2022 | n/a |
| Jun 2026 | +9.8% |
| Mar 2026 | +10.0% |
| Dec 2025 | +10.8% |
| Sep 2025 | +10.6% |
| Jun 2025 | +2.6% |
| Mar 2025 | +2.6% |
| Dec 2024 | +3.4% |
| Sep 2024 | +4.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+19.8%
operating income after a 15.4% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital SOLV
| FY Dec 2025 | +24.1% |
| FY Dec 2024 | +5.5% |
| FY Dec 2023 | +11.9% |
| FY Dec 2022 | n/a |
| Jun 2026 | +19.8% |
| Mar 2026 | +20.7% |
| Dec 2025 | +24.1% |
| Sep 2025 | +25.0% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +5.5% |
| Sep 2024 | +6.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+18.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SOLV
| FY Dec 2025 | +19.0% |
| FY Dec 2024 | +8.6% |
| FY Dec 2023 | +13.9% |
| FY Dec 2022 | n/a |
| Jun 2026 | +18.0% |
| Mar 2026 | +18.6% |
| Dec 2025 | +19.0% |
| Sep 2025 | +19.2% |
| Jun 2025 | +6.4% |
| Mar 2025 | +6.5% |
| Dec 2024 | +8.6% |
| Sep 2024 | +11.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
10.50x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing SOLV
| FY Dec 2025 | 8.94x |
| FY Dec 2024 | 23.93x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 9.44x |
| Mar 2026 | 8.01x |
| Dec 2025 | 8.94x |
| Sep 2025 | 8.40x |
| Jun 2025 | 34.95x |
| Mar 2025 | 35.04x |
| Dec 2024 | 23.93x |
| Sep 2024 | 16.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$19.3B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SOLV
| FY Dec 2025 | $17.9B |
| FY Dec 2024 | $18.7B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $18.0B |
| Mar 2026 | $15.8B |
| Dec 2025 | $17.9B |
| Sep 2025 | $16.2B |
| Jun 2025 | $20.4B |
| Mar 2025 | $20.5B |
| Dec 2024 | $18.7B |
| Sep 2024 | $19.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield SOLV
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | +7.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -0.9% |
| Mar 2026 | -1.8% |
| Dec 2025 | -0.1% |
| Sep 2025 | +0.4% |
| Jun 2025 | +1.1% |
| Mar 2025 | +2.9% |
| Dec 2024 | +7.1% |
| Sep 2024 | +9.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.04x
P/E over trailing EPS growth of 276%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing SOLV
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.08x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $8.3B | $8.3B | $8.2B | $8.1B |
| Gross profit | $4.5B | $4.6B | $4.7B | $4.7B |
| Operating income | $2.2B | $1.0B | $1.7B | $1.7B |
| Net income | $1.6B | $479.0M | $1.3B | $1.3B |
| EPS (diluted) | 8.88 | 2.76 | 7.79 | 7.78 |
| Operating cash flow | $369.0M | $1.2B | $1.9B | $1.7B |
| Cash | $878.0M | $762.0M | $194.0M | n/a |
| Long-term debt | $5.0B | $7.8B | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SOLV Stock Sonar score 5/7 axes
Find similar shapesCompareSOLV ranks highest on profitability (88th percentile) and risk and compliance (68th), and lowest on growth (24th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SOLV filings, in plain words
Have members of Congress traded SOLV?
Yes. In the year to 2026-10-28, 0 House members disclosed buying SOLV and 1 House member disclosed selling it; the latest on record is a sale by James French Hill dated 2025-12-31.
Read the full summary
In the year to 2026-10-28, 0 members of Congress disclosed buying SOLV and 1 member disclosed selling it; the latest on record is a sale by James French Hill dated 2025-12-31. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
